【摘要】 目的比较硼替佐米、沙利度胺及地塞米松(VTD)与沙利度胺联合地塞米松(TD)治疗多发性骨髓瘤(MM)的疗效和不良反应情况。方法选择80例MM患者,根据治疗方法均为2组,40例采用VTD方案进行治疗,另40例采用TD方案进行治疗。比较2组患者的治疗疗效和不良反应发生情况。结果 VTD组的总有效率(77. 5%)高于TD组(55. 00%),差异有统计学意义(P <0. 05)。VTD组过敏性皮疹发生率和周围神经病变发生率均高于TD组,差异有统计学意义(P <0. 05); VTD组血小板减少症发生率(30. 00%)与TD组(15. 00%)相比,差异无统计学意义(P>0. 05);其余不良反应组间差异无统计学意义(P> 0. 05)。结论 VTD方案用于多发性骨髓瘤治疗的疗效优于TD方案,但VTD组的安全性略低于TD组。更多还原

【Abstract】 Objective To compare the efficacy and adverse reactions of bortezomi,thalidomide,dexamethasone( VTD and thalidomide combined with dexamethasone( TD) in the treatment of multiple myeloma( MM). Methods Eighty patients with MM were selected,according to the treatment methods,the 2 groups were divided into 2 groups. 40 patients were treated with VTD,and 40 others were treated with TD. The therapeutic efficacy and adverse reactions of the 2 groups were compared. Results The total efficiency rate of the VTD group( 77. 5%) was higher than that of the TD group( 55. 00%),and the difference was statistically significant( P < 0. 05). The incidence of allergic rashes and peripheral neuropathy in the VTD group were higher than that of the TD group,and the difference were statistically significant( P < 0. 05). The incidence of thrombocytopenia in the VTD group( 30. 00%) was not statistically significant compared to the TD group( 15. 00%)( P < 0. 05). The incidence of peripheral neuropathy( 22. 50%) and rash( 52. 50%) in the VTD group was higher than that of the TD group( 5. 00%,27. 50%),and the difference was statistically significant( P < 0. 05). There was no statistically significant difference between the remaining adverse reaction groups( P > 0. 05). Conclusion The effect of VTD on multiple myeloma is better than that of TD,but the safety of VTD group is slightly lower than that of TD group.更多还原